SCHEMBL5155113

SCHEMBL5155113

COC(=O)c1ccc(OC(F)(C(=O)Cc2ccc(NC(=O)OCc3ccccc3)cc2)N2CCCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
CYP3A4 P08684 2/20 0.45
TP53 P04637 2/20 0.45
FAAH O00519 1/20 0.44
EPHX2 P34913 1/20 0.44
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ELANE P08246 1/20 0.42
TPSAB1 Q15661 1/20 0.42
TPSD1 Q9BZJ3 1/20 0.42
TPSG1 Q9NRR2 1/20 0.42
TSHR P16473 1/20 0.42
MAPT P10636 3/20 0.42
HRH3 Q9Y5N1 2/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TNF P01375 1/20 0.40
NOD2 Q9HC29 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149635 0.82 MAPT (0.56) RAB9ANPC1EPHX2KMT2AMEN1
SCHEMBL5150238 0.81 P2RY1 (0.46) RAB9ANPC1EPHX2KMT2AMEN1
SCHEMBL5149795 0.80 KDM4E (0.39) RAB9ANPC1FAAHEPHX2ALDH1A1
SCHEMBL5152922 0.80 EPHX2 (0.50) RAB9ANPC1TP53FAAHEPHX2
SCHEMBL12348789 0.77 RAB9A (0.65) RAB9ANPC1CYP3A4TP53ALDH1A1
SCHEMBL5153406 0.76 MAPT (0.47) RAB9ANPC1FAAHEPHX2KMT2A
SCHEMBL5153516 0.75 ITGA4 (0.48) RAB9ANPC1TP53ALDH1A1KMT2A
SCHEMBL5155651 0.74 P2RY1 (0.45) RAB9ANPC1FAAHEPHX2KMT2A
SCHEMBL5151820 0.73 RAB9A (0.48) RAB9ANPC1ALDH1A1KMT2AMEN1
SCHEMBL5150125 0.73 ITGA4 (0.44) RAB9ANPC1TP53ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 RAB9A 2282/4885NPC1 2939/4885CYP3A4 594/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 RAB9A 1984/4885NPC1 3300/4885CYP3A4 609/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 RAB9A 2225/4885NPC1 2981/4885CYP3A4 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.